A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
Status:
Completed
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics
of galidesivir following administration of single doses by IV infusion
Phase:
Phase 1
Details
Lead Sponsor:
BioCryst Pharmaceuticals
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)